Targeted Assessment of the <i>EGFR</i> Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)
Background: Assessment of actionable <i>EGFR</i> mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid <i>EGFR</i> testing, an <i>EGFR</i>-s...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/4/955 |
| _version_ | 1797570791489929216 |
|---|---|
| author | Sandra Lassalle Véronique Hofman Simon Heeke Jonathan Benzaquen Elodie Long Michel Poudenx Elisabeth Lantéri Jacques Boutros Virginie Tanga Katia Zahaf Salomé Lalvée Virginie Lespinet Olivier Bordone Jean-Marc Félix Christelle Bonnetaud Charles Marquette Marius Ilie Paul Hofman |
| author_facet | Sandra Lassalle Véronique Hofman Simon Heeke Jonathan Benzaquen Elodie Long Michel Poudenx Elisabeth Lantéri Jacques Boutros Virginie Tanga Katia Zahaf Salomé Lalvée Virginie Lespinet Olivier Bordone Jean-Marc Félix Christelle Bonnetaud Charles Marquette Marius Ilie Paul Hofman |
| author_sort | Sandra Lassalle |
| collection | DOAJ |
| description | Background: Assessment of actionable <i>EGFR</i> mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid <i>EGFR</i> testing, an <i>EGFR</i>-specific polymerase chain reaction (PCR) assay is an alternative and simple approach compared to next generation sequencing (NGS). Here, we describe how a rapid <i>EGFR</i>-specific PCR assay can be implemented in a single laboratory center (LPCE, Nice, France) as reflex testing in treatment-naïve NSLC. Methods: A total of 901 biopsies from NSLC with more than 10% of tumor cells were prospectively and consecutively evaluated for <i>EGFR</i> mutation status between November 2017 and December 2019 using the Idylla system (Biocartis NV, Mechelen, Belgium). NGS was performed for nonsmokers with NSLC wild type for <i>EGFR</i>, <i>ALK</i>, <i>ROS1</i>, and <i>BRAF</i> and with less than 50% PD-L1 positive cells using the Hotspot panel (Thermo Fisher Scientific, Waltham, MA, USA). Results: Results were obtained from 889/901 (97%) biopsies with detection of <i>EGFR</i> mutations in 114/889 (13%) cases using the Idylla system. Among the 562 <i>EGFR</i> wild type tumors identified with Idylla, NGS detected one actionable and one nonactionable <i>EGFR</i> mutation. Conclusions: Rapid and targeted assessment of <i>EGFR</i> mutations in treatment-naïve NSLC can be implemented in routine clinical practice. However, it is mandatory to integrate this approach into a molecular algorithm that allows evaluation of potentially actionable genomic alterations other than <i>EGFR</i> mutations. |
| first_indexed | 2024-03-10T20:31:23Z |
| format | Article |
| id | doaj.art-cce41d000a504ac5a9cd2aacafb33c04 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T20:31:23Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-cce41d000a504ac5a9cd2aacafb33c042023-11-19T21:26:34ZengMDPI AGCancers2072-66942020-04-0112495510.3390/cancers12040955Targeted Assessment of the <i>EGFR</i> Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)Sandra Lassalle0Véronique Hofman1Simon Heeke2Jonathan Benzaquen3Elodie Long4Michel Poudenx5Elisabeth Lantéri6Jacques Boutros7Virginie Tanga8Katia Zahaf9Salomé Lalvée10Virginie Lespinet11Olivier Bordone12Jean-Marc Félix13Christelle Bonnetaud14Charles Marquette15Marius Ilie16Paul Hofman17Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceFHU OncoAge, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceFHU OncoAge, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceDepartment of Pneumology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceHospital-Related Biobank (BB-0033-00025), Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceHospital-Related Biobank (BB-0033-00025), Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceHospital-Related Biobank (BB-0033-00025), Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceFHU OncoAge, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceLaboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, FranceBackground: Assessment of actionable <i>EGFR</i> mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid <i>EGFR</i> testing, an <i>EGFR</i>-specific polymerase chain reaction (PCR) assay is an alternative and simple approach compared to next generation sequencing (NGS). Here, we describe how a rapid <i>EGFR</i>-specific PCR assay can be implemented in a single laboratory center (LPCE, Nice, France) as reflex testing in treatment-naïve NSLC. Methods: A total of 901 biopsies from NSLC with more than 10% of tumor cells were prospectively and consecutively evaluated for <i>EGFR</i> mutation status between November 2017 and December 2019 using the Idylla system (Biocartis NV, Mechelen, Belgium). NGS was performed for nonsmokers with NSLC wild type for <i>EGFR</i>, <i>ALK</i>, <i>ROS1</i>, and <i>BRAF</i> and with less than 50% PD-L1 positive cells using the Hotspot panel (Thermo Fisher Scientific, Waltham, MA, USA). Results: Results were obtained from 889/901 (97%) biopsies with detection of <i>EGFR</i> mutations in 114/889 (13%) cases using the Idylla system. Among the 562 <i>EGFR</i> wild type tumors identified with Idylla, NGS detected one actionable and one nonactionable <i>EGFR</i> mutation. Conclusions: Rapid and targeted assessment of <i>EGFR</i> mutations in treatment-naïve NSLC can be implemented in routine clinical practice. However, it is mandatory to integrate this approach into a molecular algorithm that allows evaluation of potentially actionable genomic alterations other than <i>EGFR</i> mutations.https://www.mdpi.com/2072-6694/12/4/955lung cancer<i>EGFR</i>targeted sequencingnext generation sequencing |
| spellingShingle | Sandra Lassalle Véronique Hofman Simon Heeke Jonathan Benzaquen Elodie Long Michel Poudenx Elisabeth Lantéri Jacques Boutros Virginie Tanga Katia Zahaf Salomé Lalvée Virginie Lespinet Olivier Bordone Jean-Marc Félix Christelle Bonnetaud Charles Marquette Marius Ilie Paul Hofman Targeted Assessment of the <i>EGFR</i> Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) Cancers lung cancer <i>EGFR</i> targeted sequencing next generation sequencing |
| title | Targeted Assessment of the <i>EGFR</i> Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
| title_full | Targeted Assessment of the <i>EGFR</i> Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
| title_fullStr | Targeted Assessment of the <i>EGFR</i> Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
| title_full_unstemmed | Targeted Assessment of the <i>EGFR</i> Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
| title_short | Targeted Assessment of the <i>EGFR</i> Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) |
| title_sort | targeted assessment of the i egfr i status as reflex testing in treatment naive non squamous cell lung carcinoma patients a single laboratory experience lpce nice france |
| topic | lung cancer <i>EGFR</i> targeted sequencing next generation sequencing |
| url | https://www.mdpi.com/2072-6694/12/4/955 |
| work_keys_str_mv | AT sandralassalle targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT veroniquehofman targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT simonheeke targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT jonathanbenzaquen targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT elodielong targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT michelpoudenx targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT elisabethlanteri targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT jacquesboutros targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT virginietanga targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT katiazahaf targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT salomelalvee targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT virginielespinet targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT olivierbordone targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT jeanmarcfelix targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT christellebonnetaud targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT charlesmarquette targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT mariusilie targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance AT paulhofman targetedassessmentoftheiegfristatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance |